Clinical Trials Logo
  1. Home
  2. Chronic Kidney Disease
  3. NCT02813642
  4. Details
NCT02813642 Clinical Trial

Evaluation of Cardiovascular Risk Factors in Incident Dialysis Patients

Chronic Kidney Disease Clinical Trial

Official title:
Evaluation of Non Traditional Cardiovascular Risk Factors in Chronic Kidney Disease Patients Starting Dialysis

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02813642
Other study ID # UF8851
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date December 8, 2011
Est. completion date February 2027

Study information
Verified date April 2022
Source University Hospital, Montpellier
Contact Jean-Paul Cristol, Prof
Phone +33(0)4 67 33 83 15
Email jp-cristol@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the relationships between bone mineral markers levels at dialysis start and vascular calcification progression during a 2 year follow up

Recruitment information / eligibility
Status Recruiting
Enrollment 400
Est. completion date February 2027
Est. primary completion date December 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Patient who has signed the written consent form - Patient with chronic renal failure starting dialysis therapy Exclusion Criteria: - Pregnancy - Patient with chronic renal failure not yet on dialysis therapy

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• Plasma osteoprotegerin level
dosage of plasma osteoprotegerin
• Plasma fibroblast growth factor 23 level
dosage of plasma fibroblast growth factor 23
Procedure:
• Vascular calcification score
measurement of vascular calcification score by X-ray of the lateral abdominal aorta

Locations
Country Name City State
France Centre Hémodialyse du Lez Castelnau Le Lez
France AIDER Montpellier
France CHU Montpellier, Nephrology department Montpellier
France CH Nimes, Nephrology department Nimes
France CH Perpignan, Nephrology department Perpignan

Sponsors (1)
Lead Sponsor Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Progression of vascular calcifications during a 2 year follow up according to plasma osteoprotegerin level at inclusion osteoprotegerin will be measured in picomol/L; vascular calcifications will be measured at inclusion and after the 2 year follow up 2 years after inclusion
Secondary Progression of vascular calcifications during a 2 year follow up according to plasma fibroblast growth factor 23 level at inclusion fibroblast growth factor 23 will be measured in RU/milliliter; vascular calcifications will be measured at inclusion and after the 2 year follow up 2 years after inclusion
Secondary Occurence of cardiovascular events during a 2 year follow up 2 years after inclusion
See also
  Status Clinical Trial Phase
Completed NCT05491642 - A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses Phase 1
Recruiting NCT06363097 - Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
Terminated NCT04043026 - The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
Completed NCT05318014 - Low-protein Formula Supplements in Chronic Kidney Disease N/A
Active, not recruiting NCT06071065 - Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients N/A
Completed NCT02878317 - Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
Not yet recruiting NCT06039254 - Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function Phase 1
Recruiting NCT03160326 - The QUALITY Vets Project: Muscle Quality and Kidney Disease
Completed NCT02836574 - A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease Phase 2
Withdrawn NCT02885545 - The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial Phase 4
Completed NCT02888171 - Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency N/A
Completed NCT02875886 - DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease Phase 4
Completed NCT02896309 - The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity N/A
Completed NCT02756520 - Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
Active, not recruiting NCT02483039 - Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization N/A
Terminated NCT02543177 - Optimised Procedure in Patients With NSTEMI and CKD N/A
Completed NCT02992548 - Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease Phase 4
Completed NCT02369549 - Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease Phase 3
Recruiting NCT02205944 - Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes N/A
Active, not recruiting NCT02231138 - Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Phase 4